Successful desensitization of a patient with cetuximab hypersensitivity: A case report. 2019

Mohammad Solduzian, and Saeed Anvari, and Hamidreza Taghvaye Masoumi, and Farhad Shahi, and Zahra Jahangard-Rafsanjani
1 Clinical Pharmacy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

BACKGROUND Severe hypersensitivity reaction is a dangerous adverse drug reaction in patients receiving cetuximab. It requires drug discontinuation and medical management. METHODS A 48-year-old man, previously diagnosed with metastatic colorectal cancer, was admitted for therapy continuation. During the first infusion of cetuximab, the patient experienced acute signs of hypersensitivity reactions. The treatment team decided to administer cetuximab employing the desensitization protocol. CONCLUSIONS This study reports a severe hypersensitivity reaction to cetuximab in an adult patient with colorectal cancer. This patient was successfully managed with a new safe and rapid desensitization protocol.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003888 Desensitization, Immunologic Immunosuppression by the administration of increasing doses of antigen. Though the exact mechanism is not clear, the therapy results in an increase in serum levels of allergen-specific IMMUNOGLOBULIN G, suppression of specific IgE, and an increase in suppressor T-cell activity. Allergen Immunotherapy,Allergy Shots,Hyposensitization Therapy,Immunotherapy, Allergen,Venom Immunotherapy,Immunologic Desensitization,Therapy, Hyposensitization,Allergen Immunotherapies,Allergy Shot,Desensitizations, Immunologic,Hyposensitization Therapies,Immunologic Desensitizations,Immunotherapy, Venom,Shot, Allergy,Venom Immunotherapies
D004342 Drug Hypersensitivity Immunologically mediated adverse reactions to medicinal substances used legally or illegally. Allergy, Drug,Hypersensitivity, Drug,Drug Allergy,Allergies, Drug,Drug Allergies,Drug Hypersensitivities,Hypersensitivities, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068818 Cetuximab A chimeric monoclonal antibody that functions as an ANTINEOPLASTIC AGENT through its binding to the EPIDERMAL GROWTH FACTOR RECEPTOR, where it prevents the binding and signaling action of cell growth and survival factors. C225,Erbitux,IMC C225,IMC-C225,MAb C225
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D015179 Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI. Colorectal Cancer,Colorectal Carcinoma,Colorectal Tumors,Neoplasms, Colorectal,Cancer, Colorectal,Cancers, Colorectal,Carcinoma, Colorectal,Carcinomas, Colorectal,Colorectal Cancers,Colorectal Carcinomas,Colorectal Neoplasm,Colorectal Tumor,Neoplasm, Colorectal,Tumor, Colorectal,Tumors, Colorectal

Related Publications

Mohammad Solduzian, and Saeed Anvari, and Hamidreza Taghvaye Masoumi, and Farhad Shahi, and Zahra Jahangard-Rafsanjani
April 2021, Medicine and pharmacy reports,
Mohammad Solduzian, and Saeed Anvari, and Hamidreza Taghvaye Masoumi, and Farhad Shahi, and Zahra Jahangard-Rafsanjani
January 2015, Case reports in immunology,
Mohammad Solduzian, and Saeed Anvari, and Hamidreza Taghvaye Masoumi, and Farhad Shahi, and Zahra Jahangard-Rafsanjani
January 2007, American journal of therapeutics,
Mohammad Solduzian, and Saeed Anvari, and Hamidreza Taghvaye Masoumi, and Farhad Shahi, and Zahra Jahangard-Rafsanjani
November 2007, American journal of hematology,
Mohammad Solduzian, and Saeed Anvari, and Hamidreza Taghvaye Masoumi, and Farhad Shahi, and Zahra Jahangard-Rafsanjani
December 2006, Minerva pediatrica,
Mohammad Solduzian, and Saeed Anvari, and Hamidreza Taghvaye Masoumi, and Farhad Shahi, and Zahra Jahangard-Rafsanjani
May 2016, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology,
Mohammad Solduzian, and Saeed Anvari, and Hamidreza Taghvaye Masoumi, and Farhad Shahi, and Zahra Jahangard-Rafsanjani
September 2018, Therapie,
Mohammad Solduzian, and Saeed Anvari, and Hamidreza Taghvaye Masoumi, and Farhad Shahi, and Zahra Jahangard-Rafsanjani
August 2008, Journal of medical case reports,
Mohammad Solduzian, and Saeed Anvari, and Hamidreza Taghvaye Masoumi, and Farhad Shahi, and Zahra Jahangard-Rafsanjani
September 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology,
Mohammad Solduzian, and Saeed Anvari, and Hamidreza Taghvaye Masoumi, and Farhad Shahi, and Zahra Jahangard-Rafsanjani
January 2015, Journal of investigational allergology & clinical immunology,
Copied contents to your clipboard!